DrugPatentWatch Database Preview
VICTOZA Drug Profile
When do Victoza patents expire, and what generic alternatives are available?
Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and fourteen patent family members in twenty-nine countries.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the liraglutide recombinant profile page.
Summary for VICTOZA
| International Patents: | 214 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 16 |
| Clinical Trials: | 100 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VICTOZA |
| Drug Sales Revenues: | Drug sales revenues for VICTOZA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VICTOZA |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for VICTOZA |
| DailyMed Link: | VICTOZA at DailyMed |
Pharmacology for VICTOZA
| Drug Class | GLP-1 Receptor Agonist |
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Medical Subject Heading (MeSH) Categories for VICTOZA
Synonyms for VICTOZA
| 204656-20-2 |
| AKOS037435224 |
| Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37) |
| CHEBI:71193 |
| EX-A2418 |
| GTPL1133 |
| H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(|A-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| HSDB 8205 |
| Liraglutida |
| Liraglutida [INN-Spanish] |
| Liraglutide |
| Liraglutide [USAN:INN:BAN:JAN] |
| Liraglutidum |
| Liraglutidum [INN-Latin] |
| MolPort-044-560-360 |
| N(sup 26)-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide |
| N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide |
| N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide |
| NN 2211 |
| NN-2211 |
| NN2211 |
| NNC 90-1170 |
| s8256 |
| Saxenda |
| SCHEMBL20511941 |
US Patents and Regulatory Information for VICTOZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for VICTOZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ➤ Sign Up | ➤ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ➤ Sign Up | ➤ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ➤ Sign Up | ➤ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ➤ Sign Up | ➤ Sign Up |
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for VICTOZA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | ➤ Sign Up |
International Patents for VICTOZA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2006116414 | ➤ Sign Up |
| Hungary | 227021 | ➤ Sign Up |
| Israel | 261169 | ➤ Sign Up |
| Japan | 2004535442 | ➤ Sign Up |
| Denmark | 1412384 | ➤ Sign Up |
| Australia | 2712899 | ➤ Sign Up |
| Israel | 135255 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for VICTOZA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | 14C0085 | France | ➤ Sign Up | PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 2209800 | C300698 | Netherlands | ➤ Sign Up | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| 2597103 | 2017/015 | Ireland | ➤ Sign Up | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912 |
| 2209800 | 1490067-4 | Sweden | ➤ Sign Up | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918 |
| 2209800 | 122014000114 | Germany | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 0944648 | SPC034/2009 | Ireland | ➤ Sign Up | SPC034/2009: 20101001, EXPIRES: 20220821 |
| 0944648 | 09C0054 | France | ➤ Sign Up | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
